Here's why the big Canadian cannabis producer's new line of cannabis drinks won't hit shelves in January as planned.
Momentum from its CEO's comments earlier this week continues.
The big drugmaker's top executives laid out a vision for AbbVie's future at the J.P. Morgan Healthcare Conference this week.
Investors are excited about a new CBD bill in the U.S. House of Representatives.
The biotech is throwing in the towel on an experimental painkiller after receiving a thumbs-down from two FDA advisory committees.
Investors loved what they saw in the Canadian cannabis producer's fiscal 2020 Q1 update.
For the leader of robotic surgical systems, the trends are a boost to business prospects.
The Canadian cannabis producer delivered exactly what investors wanted with its latest quarterly update.
Investors responded positively to the drugmaker's sneak peek at its Q4 and full-year results.
The company's battle with former partner Align Technology is heating up.
Here's what you really need to know about the Canadian cannabis producer's disappointing Q2 results.
One exception to the list of big winners: Aurora Cannabis.
The British drugmaker throws in the towel on a study that could have positioned Epanova to compete against Amarin's Vascepa.
Abiomed's sneak peek at its Q3 results leaves investors underwhelmed.
This seemingly unlikely trio could help you retire in style.
A big drugmaker, a global utility company, and an intriguing REIT top my list of great dividend stocks to buy.
It's volatile. It's risky. But Canopy Growth just might be a big winner this year.
The third buyout offer in less than two months is lighting a fire beneath this biotech stock.
This dividend darling was too attractive to overlook.
ADMA's sneak peek at its Q4 results and an encouraging 2020 strategic update are exciting investors.